Clinical trial for COPD (Chronic Obstructive Pulmonary Disease)
Official title Effects of Blood Flow Restriction Aerobic Exercise on Inflammation, Hypoxia, Exercise Capacity, and Lung Function in COPD
ClinicalTrials.gov ID: NCT07261293
What this study is testing
- What it's testing
- The study wants to see if adding blood‑flow‑restriction to low‑intensity aerobic exercise changes inflammation, oxygen levels, exercise ability, lung function, muscle strength, and quality of life compared with usual pulmonary rehab.
- Who it's for
- Adults who have chronic obstructive pulmonary disease (COPD).
- What's involved
- Participants will join a pulmonary rehab program; one group does low‑intensity aerobic exercise with a cuff that limits blood flow, the other does moderate‑intensity aerobic exercise without the cuff. All sessions are supervised by a physiotherapist, twice a week for eight weeks, with health measurements taken before, midway, and after the program.
- Time commitment
- The study lasts about 8 weeks with two supervised visits each week and a few assessment visits.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 80
You may be able to join if
- Individuals aged between 40 and 80 years
- Clinically stable patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) according to GOLD 2024 criteria with post-bronchodilator...
- Stable clinical condition (no acute exacerbation within the past 4 weeks)
- Individuals clinically evaluated and approved as suitable for pulmonary rehabilitation (PR) participation by a cardiology specialist
- Functional capacity sufficient to participate in PR (e.g., 6-Minute Walk Test ≥150 m)
You likely can't join if
- Acute exacerbation of COPD, hospitalization, or systemic corticosteroid treatment within the past 4 weeks
- Severe cardiovascular disease (uncontrolled hypertension \>180/110 mmHg, myocardial infarction within the past 6 months, unstable angina, congestive...
- Neurological or orthopedic conditions significantly limiting lower-extremity function (e.g., hemiplegia, amputation, severe osteoarthritis, knee...
- Severe renal impairment (GFR \<30 mL/min/1.73 m²) or severe hepatic failure
- History of lower-extremity surgery within the past 3 months
- Active malignancy or systemic infection
See the full eligibility criteria
- Individuals aged between 40 and 80 years
- Clinically stable patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) according to GOLD 2024 criteria with post-bronchodilator FEV₁/FVC \< 0.70
- Stable clinical condition (no acute exacerbation within the past 4 weeks)
- Individuals clinically evaluated and approved as suitable for pulmonary rehabilitation (PR) participation by a cardiology specialist
- Functional capacity sufficient to participate in PR (e.g., 6-Minute Walk Test ≥150 m)
- No contraindications to blood flow restriction (BFR) training (e.g., no peripheral vascular disease, no active thrombosis)
- Ability to understand and follow instructions (adequate auditory and cognitive function)
- Acute exacerbation of COPD, hospitalization, or systemic corticosteroid treatment within the past 4 weeks
- Severe cardiovascular disease (uncontrolled hypertension \>180/110 mmHg, myocardial infarction within the past 6 months, unstable angina, congestive heart failure NYHA Class III-IV)
- Neurological or orthopedic conditions significantly limiting lower-extremity function (e.g., hemiplegia, amputation, severe osteoarthritis, knee prosthesis)
- Severe renal impairment (GFR \<30 mL/min/1.73 m²) or severe hepatic failure
- History of lower-extremity surgery within the past 3 months
- Active malignancy or systemic infection
- Anemia or chronic inflammatory/autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease)
- History of venous thromboembolism
- Peripheral arterial disease
- Physician-diagnosed sarcopenia
- Psychiatric disorders (major depression, dementia, psychotic disorders) limiting adherence to the study protocol
The study team makes the final eligibility decision.
Where it is enrolling
- Istanbul, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Istanbul, Turkey (Türkiye). Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.